News >

Abiraterone Associated With Improved PROs in Metastatic Prostate Cancer

Jason Harris
Published: Tuesday, Jan 16, 2018

Kim N. Chi, MD
Kim N. Chi, MD
Men with newly diagnosed metastatic castration-naïve prostate cancer in the global LATITUDE trial reported clinical improvements in pain progression, prostate cancer symptoms, fatigue, functional decline, and overall health-related quality of life (HR-QOL) following treatment with abiraterone acetate (Zytiga) plus prednisone.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication